Integrated pharmaceutical organisation Encube Ethicals has opened a new high potency manufacturing facility for topical formulations, the company has announced.
Manufacturing
The new site, based at the company’s site in Goa, follows a $4 million investment last year to bolster its topical manufacturing capabilities. The facility includes an in-house isolator technology that caters for topical products, which include highly potent active pharmaceutical ingredients (HPAPIs), such as pesticides, immunosuppressants and skin oncology drugs.
The facility was built in response to customer and market demand for Encube’s services and adds an additional manufacturing line to the company’s portfolio.
Mehul Shah, managing director and founder of Encube Ethicals, said: “There is a real gap in the market for contract service providers that can provide innovative and cost-effective topical manufacturing capabilities for products that include highly potent actives.
“As a result, we have experienced high demand for these services and chose to invest in a new facility to increase our capacity. Now that we’re fully operational, we can continue to cater for new small pharma, biotech and virtual customers, as well as continue to support our current multi-national customers who are entering the high potency topical space.”